Therapy of retained fetal membranes in cattle: Comparison of two treatment protocols.

Anim Reprod Sci

Clinic for Ruminants, Vetsuisse-Faculty, Bremgartenstrasse 109a, University of Bern, 3012 Bern, Switzerland. Electronic address:

Published: July 2019

This prospective study was conducted to compare two treatment protocols for retained foetal membranes (RFM) in cattle. The routine therapy consisting of intrauterine tetracycline boluses was compared with the administration of ozone foam, both intrauterine therapies without attempts to manually remove the placenta. Cows undergoing caesarean section, suffering from uterine torsion or prolapse of the uterus, and other illnesses than RFM on the first day post-partum were excluded. Values for baseline variables as age, breed, yearly milk yield, parity, pregnancy duration, calving season and number of routine intrauterine treatments were not different between the groups. Number of days with rectal temperature >39.7 °C within the first 10 days in milk (DIM) were greater in the ozone group. Number of escape therapies were recorded when there was imposing of this therapy as a result of cows having a fever (based on rectal temperature >39.7 °C) and a significant reduced food intake. Escape therapies consisted of parenteral administration of tetracyclines and NSAIDS during the first 10 DIM. Number of escape therapies, however, was not different between the groups. Results from use of a logistic regression model with fever as a dichotomous variable indicated there was no effect of breed, studbook, type of stall, pasture, business and no effect of age or milk yield. In a second assessment, cows were evaluated until 200 DIM. Results from a survival analysis indicated group (Te/Oz) did not affect rate of culling from the herd.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anireprosci.2019.04.013DOI Listing

Publication Analysis

Top Keywords

escape therapies
12
treatment protocols
8
milk yield
8
rectal temperature
8
temperature >397 °c
8
number escape
8
therapy retained
4
retained fetal
4
fetal membranes
4
membranes cattle
4

Similar Publications

Roadmap to discovery and early development of an mRNA loaded LNP formulation for liver therapeutic genome editing.

Expert Opin Drug Deliv

January 2025

Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, UK.

Introduction: mRNA therapeutics were a niche area in drug development before COVIDvaccines. Now they are used in vaccine development, for non-viral therapeuticgenome editing, chimericantigen receptor T  (CAR T) celltherapies and protein replacement.  mRNAis large, charged, and easily degraded by nucleases.

View Article and Find Full Text PDF

Hepatocellular carcinoma (HCC) is a major global health issue characterized by poor prognosis and complex tumor biology. One of the critical components of the HCC tumor microenvironment (TME) is tumor-associated macrophages (TAMs), which play a pivotal role in modulating tumor growth, immune evasion, and metastasis. Macrophages are divided into two major subtypes: pro-inflammatory M1 and anti-inflammatory M2, both of which may exist in TME with altered function and proportion.

View Article and Find Full Text PDF

Targeting CD200 in Breast Cancer: Opportunities and Challenges in Immunotherapeutic Strategies.

Int J Mol Sci

December 2024

Vascular Biology Program, Department of Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.

One of the key factors that contribute to tumor progression and resistance is the immunosuppressive microenvironment of the tumor. CD200 is a recently identified cell surface glycoprotein recognized as an important molecule in breast cancer for its versatile modulation of the immune response via its receptor, CD200R. The interaction between CD200 and CD200R suppresses the immune activities against tumor cells and allows them to be undetected and, in doing so, to escape from the destructive capability of the immune cells.

View Article and Find Full Text PDF

Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists.

Cancer Treat Rev

January 2025

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120 Guangzhou, China; Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120 Guangzhou, China. Electronic address:

Background: Ovarian function suppression (OFS) has emerged as a crucial adjuvant therapy for premenopausal breast cancer patients. Some patients fail to achieve complete OFS with commonly used OFS drugs. The definition of incomplete OFS remains unclear, and large-scale data on its incidence are lacking.

View Article and Find Full Text PDF

Noncanonical UPR factor CREB3L2 drives immune evasion of triple-negative breast cancer through Hedgehog pathway modulation in T cells.

Sci Adv

January 2025

Zhejiang Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China.

The unfolded protein response (UPR) pathway is crucial for tumorigenesis, mainly by regulating cancer cell stress responses and survival. However, whether UPR factors facilitate cell-cell communication between cancer cells and immune cells to drive cancer progression remains unclear. We found that adenosine 3',5'-monophosphate response element-binding protein 3-like protein 2 (CREB3L2), a noncanonical UPR factor, is overexpressed and activated in triple-negative breast cancer, where its cleavage releases a C-terminal fragment that activates the Hedgehog pathway in neighboring CD8+ T cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!